Cargando…

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

BACKGROUND: Hypomethylating agents (HMAs) have shown efficacy in the treatment of hematological malignancies and are indicated for the treatment of chronic myelomonocytic leukemia (CMML). While the HMA decitabine, in its intravenous formulation, has been used since 2006 for the treatment of CMML, us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheel, Ankur, Bae, Junu, Asada, Ashlee, Otterson, Gregory A., Baliga, Ragavendra R., Koenig, Kristin L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845814/ https://www.ncbi.nlm.nih.gov/pubmed/36653885 http://dx.doi.org/10.1186/s40959-023-00153-6

Ejemplares similares

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2021)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Correction to: Decitabine/Cedazuridine: First Approval
por: Dhillon, Sohita
Publicado: (2020)

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
por: Briski, Robert, et al.
Publicado: (2023)

S172: PHASE 1/2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH VENETOCLAX IN TREATMENT-NAÏVE HIGHER-RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
por: Bataller, Alex, et al.
Publicado: (2023)

P741: PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL
por: Shortt, Jake, et al.
Publicado: (2023)

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study
por: Savona, Michael R., et al.
Publicado: (2021)

A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia
por: Santini, V, et al.
Publicado: (2018)

Acute myelomonocytic leukemia and T-lymphoblastic lymphoma as simultaneous bilineage hematologic malignancy treated with decitabine: A case report
por: Jeon, So-Yeon, et al.
Publicado: (2023)

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study
por: Garcia-Manero, Guillermo, et al.
Publicado: (2021)

Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report
por: Liu, Huan, et al.
Publicado: (2018)

P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
por: Robert Savona, Michael, et al.
Publicado: (2023)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model
por: Ramsey, Haley E., et al.
Publicado: (2020)

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy
por: Agasthi, Pradyumna, et al.
Publicado: (2018)

How I diagnose and treat chronic myelomonocytic leukemia
por: Patnaik, Mrinal M.
Publicado: (2022)

The Genomic Landscape of Juvenile Myelomonocytic Leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2015)

Lysozyme nephropathy in chronic myelomonocytic leukemia
por: Patel, Ami B., et al.
Publicado: (2019)

Diagnosis and treatment of chronic myelomonocytic leukemia
por: Kwon, Jihyun
Publicado: (2021)

Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021)

Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report
por: Pelkey, Lauren J, et al.
Publicado: (2022)

Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival
por: Geissler, Klaus, et al.
Publicado: (2021)

Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report
por: DENG, QI, et al.
Publicado: (2015)

Decitabine Induced Transient Cardiomyopathy: A Case Report
por: De, Chitradeep, et al.
Publicado: (2012)

COVID-19 in a patient with chronic myelomonocytic leukemia: a twisting tale
por: Jain, Ankur, et al.
Publicado: (2020)

Molecular Targets for the Treatment of Juvenile Myelomonocytic Leukemia
por: Liu, Xiaoling, et al.
Publicado: (2012)

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia
por: Patnaik, M M, et al.
Publicado: (2016)

Fighting back against chronic myelomonocytic leukemia
por: Jo, Deog-Yeon
Publicado: (2013)

Acute Myelomonocytic Leukemia Presenting as Perianal Pain
por: Iqbal, Syma, et al.
Publicado: (2018)

Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia
por: Beke, Allan, et al.
Publicado: (2020)

Endogenous and combination retinoids are active in myelomonocytic leukemias
por: di Martino, Orsola, et al.
Publicado: (2021)

Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia
por: Fiñana, Claudia, et al.
Publicado: (2022)

Multistep pathogenesis of chronic myelomonocytic leukemia in patients
por: Geissler, Klaus, et al.
Publicado: (2022)

Erythroderma in a patient with chronic myelomonocytic leukemia
por: Trepanowski, Nicole, et al.
Publicado: (2022)

Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia
por: Zack, Marie-Therese, et al.
Publicado: (2022)

Co‐occurrence of hypertrophic cardiomyopathy and juvenile myelomonocytic leukemia in a neonate with Noonan syndrome, leading to premature death
por: Tamura, Akihiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q7gve4t8l67scjh9jo6niobukf